Stockscreener 앱 받기
1.90
3.83%
0.07
전일 마감가:
$1.83
열려 있는:
$1.83
하루 거래량:
615.28K
Relative Volume:
0.52
시가총액:
$123.47M
수익:
-
순이익/손실:
$-117.50M
주가수익비율:
-0.7917
EPS:
-2.4
순현금흐름:
$-114.31M
1주 성능:
+9.20%
1개월 성능:
+2.15%
6개월 성능:
-26.36%
1년 성능:
-71.68%
1일 변동 폭
$1.81
$1.935
1주일 범위
$1.70
$1.935
52주 변동 폭
$1.31
$8.23
엔카르타 Stock (NKTX) Company Profile
명칭
Nkarta Inc
전화
(925) 407-1049
주소
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
NKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.90 | 123.47M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
엔카르타 Stock (NKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-08-14 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-07-28 | 개시 | Needham | Buy |
| 2022-07-18 | 개시 | SVB Leerink | Outperform |
| 2022-03-11 | 개시 | Raymond James | Outperform |
| 2022-03-08 | 개시 | H.C. Wainwright | Buy |
| 2022-01-06 | 개시 | William Blair | Outperform |
| 2021-11-18 | 개시 | SMBC Nikko | Outperform |
| 2021-07-16 | 개시 | Oppenheimer | Outperform |
| 2020-08-04 | 개시 | Cowen | Outperform |
| 2020-08-04 | 개시 | Evercore ISI | Outperform |
| 2020-08-04 | 개시 | Mizuho | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
엔카르타 주식(NKTX)의 최신 뉴스
Two Sigma Advisers LP Acquires New Stake in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta Names Shawn Rose as Chief Medical Officer - marketscreener.com
Nkarta Announces Leadership Change with New CMO - TipRanks
Nkarta appoints Shawn Rose as CMO, head of R&D - TipRanks
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of - GlobeNewswire
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Nuveen Asset Management LLC - Defense World
ProShare Advisors LLC Invests $45,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Deutsche Bank AG Has $107,000 Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Millennium Management LLC Boosts Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
BNP Paribas Financial Markets Invests $507,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade - MSN
Equities Analysts Issue Forecasts for Nkarta FY2025 Earnings - Defense World
Leerink Partnrs Analysts Lower Earnings Estimates for Nkarta - Defense World
Price T Rowe Associates Inc. MD Acquires 7,030 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
William Blair Comments on Nkarta’s Q2 Earnings (NASDAQ:NKTX) - Defense World
Nkarta (NASDAQ:NKTX) Earns “Market Perform” Rating from William Blair - Defense World
Needham & Company LLC Lowers Nkarta (NASDAQ:NKTX) Price Target to $10.00 - Defense World
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Dimensional Fund Advisors LP Has $1.42 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Stifel Financial Corp - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Nkarta, Inc. Reports Q1 2025 Financial Results - TipRanks
Nkarta stock rating downgraded at William Blair to Market Perform By Investing.com - Investing.com South Africa
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Benzinga
Nkarta (NKTX) Experiences Downgrade Amid Clinical Protocol Changes | NKTX Stock News - GuruFocus
NKTX's Strategic Moves to Reach Clinical Milestones and Extend C - GuruFocus
NKTX: William Blair Downgrades Nkarta to Market Perform | NKTX S - GuruFocus
Needham Maintains 'Buy' Rating on Nkarta (NKTX) as Price Target Adjusts | NKTX Stock News - GuruFocus
This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
NKTX: William Blair Downgrades Nkarta to Market Perform | NKTX Stock News - GuruFocus
William Blair Downgrades Nkarta to Market Perform From Outperform - marketscreener.com
Nkarta stock rating downgraded at William Blair to Market Perform - Investing.com
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
NKTX's Strategic Moves to Reach Clinical Milestones and Extend Cash Runway | NKTX Stock News - GuruFocus
Nkarta's $351.9M War Chest Funds Operations Until 2029 as Clinical Trials Expand in Autoimmune Diseases - Stock Titan
Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Wells Fargo & Company MN - Defense World
Barclays PLC Has $674,000 Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Financial Snapshot: Analyzing Nkarta Inc (NKTX)’s Key Ratio Metrics - DWinneX
11,997 Shares in Nkarta, Inc. (NASDAQ:NKTX) Purchased by Invesco Ltd. - Defense World
Uncovering the Potential of Nkarta Inc (NKTX) Stock - investchronicle.com
A stock that deserves closer examination: Nkarta Inc (NKTX) - uspostnews.com
Nkarta Inc (NKTX) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Daily Market Movement: Nkarta Inc (NKTX) Sees a -4.74 Decrease, Closing at 2.01 - DWinneX
Geode Capital Management LLC Has $2.94 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Nkarta Inc’s Market Journey: Closing Weak at 1.56, Down -4.29 - DWinneX
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Technical analysis of Nkarta Inc (NKTX) stock chart patterns - uspostnews.com
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 2.18 - DWinneX
Insider Sale Alert: Nkarta Inc [NKTX] – Is it Time to sell? - knoxdaily.com
A Tale of Resilience: Nkarta Inc Amid Stock Market Turbulence - investchronicle.com
엔카르타 (NKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엔카르타 주식 (NKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
| Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
| Hager Alicia J. | Chief Legal Officer |
Jul 16 '24 |
Sale |
8.00 |
3,396 |
27,168 |
103,819 |
| Trager James | Chief Scientific Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
150,959 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '24 |
Sale |
5.60 |
1,770 |
9,912 |
240,737 |
| Shook David | Chief Medical Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
116,524 |
| Hager Alicia J. | Chief Legal Officer |
Jun 18 '24 |
Sale |
5.60 |
727 |
4,071 |
107,215 |
| Brandenberger Ralph | Chief Technical Officer |
Jun 18 '24 |
Sale |
5.60 |
229 |
1,282 |
79,743 |
1.21%
1.51%
자본화:
|
볼륨(24시간):